Editas Medicine is a clinical-stage genome-editing company headquartered in Cambridge, Massachusetts, focused on in vivo (inside-the-body) CRISPR therapies. The company holds exclusive licenses to the Broad Institute's Cas12a patent estate and the Broad/Harvard Cas9 patent estates for human medicines, giving it meaningful intellectual-property depth in a rapidly consolidating field.
Its market positioning now centers on functional gene upregulation—turning genes on rather than knocking them out—using its clinically validated Cas12a enzyme and proprietary targeted lipid nanoparticles (LNPs), the tiny fatty carriers that deliver the editing machinery to cells. EDIT-401, the lead candidate, edits the LDLR gene in the liver to boost LDL-receptor activity and clear cholesterol. Preclinical data reported durable reductions in LDL-C of 90% or more in non-human primates, a profile management characterizes as potentially best-in-class. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The structural risk is equally clear: Editas is competing against larger, better-capitalized rivals in the in vivo space, and it remains preclinical with no approved products. Its medium-term fate depends on translating strong animal data into clean human results—a transition that has historically separated winners from also-rans in gene editing.
The pivotal catalyst is the initiation and early readout of the Phase 1/2 Strive study of EDIT-401 in HeFH. After receiving approval to begin dosing in Australia, the company expects to start patient dosing by the end of 2026, report initial safety data in Q1 2027, and follow with top-line efficacy data in the second half of 2027. Each of these checkpoints is a potential re-rating event, because they address the two questions investors care most about: is the therapy safe in humans, and does the dramatic LDL-C lowering seen in primates translate to patients?
Analyst ratings have shifted in response. Guggenheim upgraded the stock to Buy from Neutral in September 2026, citing optimism around EDIT-401, while Wells Fargo upgraded to Overweight with a $6 price target after the Australian trial clearance. H.C. Wainwright has reiterated a Buy and $5 target, and JonesTrading maintains a Buy with an $8 target. Consensus price targets cluster in the roughly $5–$6 range, though the distribution remains wide—reflecting genuine disagreement about the probability of clinical success.
Additional catalysts include potential licensing and business-development deals tied to Editas's intellectual property and delivery platform, plus the pace of cash consumption, which will determine whether the company can reach its 2027 readouts without significant new financing.
Editas operates at the intersection of gene editing and cardiovascular medicine, two areas with distinct macro sensitivities. On the science side, the sector benefits from accelerating regulatory acceptance of CRISPR-based therapies and growing investor appetite for one-time, potentially curative treatments. On the funding side, biotech is highly sensitive to interest rates: higher rates raise the cost of capital and make future, uncertain cash flows less valuable, while falling rates tend to support pre-revenue names.
The cholesterol market itself is enormous and well-established, with statins and injectable therapies such as PCSK9 inhibitors already widely used. EDIT-401's appeal rests on offering a durable, single-treatment alternative to lifelong dosing—a value proposition that resonates in a cost-conscious healthcare environment but must clear a high safety bar. Regulatory climate, reimbursement dynamics, and competition from other gene-editing and RNA-based approaches will all shape how quickly and profitably any eventual therapy could scale.
Looking toward 2026 and beyond, Editas's trajectory revolves around execution. The near-term narrative is dominated by whether the company can dose its first EDIT-401 patients and deliver credible early safety data in early 2027. Longer-term, the story broadens: if the upregulation platform works, it could be extended to other diseases of haploinsufficiency—conditions where boosting a single gene's output could restore function—potentially unlocking a much larger addressable market.
Cost-structure evolution is a critical theme. The 2024 restructuring sharply lowered operating expenses, and management has emphasized capital efficiency and non-dilutive financing, including a $125 million financing completed in 2026. Sustaining that discipline while funding clinical trials will determine margin sustainability and dilution risk. Competitive threats from peers advancing their own in vivo and RNA-based cholesterol programs, evolving regulatory expectations, and the company's capital-allocation choices all merit close monitoring.
Consensus expectations reflect cautious optimism: analyst price targets imply meaningful upside from recent levels, yet the wide dispersion of targets and the presence of some Sell and Hold ratings underscore that the market views EDIT-401's clinical readouts—not near-term financials—as the true determinant of the stock's future outlook.
I often turn to Tickeron’s AI Trend Prediction Engine when evaluating names like this one. It provides a data-driven layer that helps assess potential short-term trends and complements the fundamental analysis of clinical timelines and balance-sheet runway. This tool has become a regular part of how I cross-check sentiment signals ahead of key binary events.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EDIT saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 120 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.596). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology